The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
AAV5–Factor VIII Gene Transfer in Severe Hemophilia A
Open accessAbstract
BACKGROUND: Patients with hemophilia A rely on exogenous factor VIII to prevent bleeding in joints, soft tissue, and the central nervous system. Although successful gene transfer has been reported in patients with hemophilia B, the large size of the factor VIII coding region has precluded improved outcomes with gene therapy in patients with hemophilia A. METHODS: We infused a single intravenous dose of a codon-optimized adeno-associated virus serotype 5 (AAV5) vector encoding a B-domain-deleted human factor VIII (AAV5-hFVIII-SQ) in nine men with severe hemophilia A. Participants were enrolled sequentially into one of three dose cohorts (low dose [one participant], intermediate dose [one participant], and high dose [seven participants]) and were followed through 52 weeks. RESULTS: Factor VIII activity levels remained at 3 IU or less per deciliter in the recipients of the low or intermediate dose. In the high-dose cohort, the factor VIII activity level was more than 5 IU per deciliter between weeks 2 and 9 after gene transfer in all seven participants, and the level in six participants increased to a normal value (>50 IU per deciliter) that was maintained at 1 year after receipt of the dose. In the high-dose cohort, the median annualized bleeding rate among participants who had previously received prophylactic therapy decreased from 16 events before the study to 1 event after gene transfer, and factor VIII use for participant-reported bleeding ceased in all the participants in this cohort by week 22. The primary adverse event was an elevation in the serum alanine aminotransferase level to 1.5 times the upper limit of the normal range or less. Progression of preexisting chronic arthropathy in one participant was the only serious adverse event. No neutralizing antibodies to factor VIII were detected. CONCLUSIONS: The infusion of AAV5-hFVIII-SQ was associated with the sustained normalization of factor VIII activity level over a period of 1 year in six of seven participants who received a high dose, with stabilization of hemostasis and a profound reduction in factor VIII use in all seven participants. In this small study, no safety events were noted, but no safety conclusions can be drawn. (Funded by BioMarin Pharmaceutical; ClinicalTrials.gov number, NCT02576795 ; EudraCT number, 2014-003880-38 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“both transgene products, FVIII-SQ and FIX-R338L, demonstrate variable activity measurements in OSA versus chromogenic assay (CSA) determinants of factor activity that are reproducible across trials.144,145,149,152”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [149]
In the citing paper
“multiple HA and HB trials have demonstrated ≥10-fold variability in FVIII:C/FIX:C with the same vector and dose (Harrington et al., 2020, WFH Virtual Summit, conference).145,149,150,153”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [149]
In the citing paper
“Corticosteroids are the most commonly used agents to resolve transaminitis, however, its relationship with resolution by corticosteroids and T-cell response are not always clear as observed in a hemophilia A trial (28, 105).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [28]
In the citing paper
“clinical gene therapy using a codon-optimized exogenous construct to compensate for mutations in a nuclear gene (e.g. hemophilia, [69]) is ongoing”
From Codon optimization is an essential parameter for the efficient allotopic expression of mtDNA genes (2020) · cites this paper as [69]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationProphylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia
Manco-Johnson, M. J., Abshire, T. C., Shapiro, A. D., Riske, B., Hacker, M. R., Kilcoyne, R., Ingram, J. D., Manco-Johnson, M. L., Funk, S., Jacobson, L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067659 · Cited by 1,950
Guidelines for the management of hemophilia
Srivastava, A., Brewer, A., Mauser‐Bunschoten, E. P., Key, N. S., Kitchen, S., Llinás, A. M., Ludlam, C. A., Mahlangu, J. N., Mulder, K., Poon, M., et al. (2012) · Haemophilia · doi:10.1111/j.1365-2516.2012.02909.x · Cited by 1,949
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Self-citationAnalysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection
Zincarelli, C., Soltys, S., Rengo, G., & Rabinowitz, J. E. (2008) · Molecular Therapy · doi:10.1038/mt.2008.76 · Cited by 1,490
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407309 · Cited by 1,273
Self-citationGene therapy returns to centre stage
Naldini, L. (2015) · Nature · doi:10.1038/nature15818 · Cited by 1,184
The hemophilias--from royal genes to gene therapy
Mannucci, P. M., & Tuddenham, E. G. D. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106073442307 · Cited by 1,110
Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant
George, L. A., Sullivan, S. K., Giermasz, A., Rasko, J. E. J., Samelson-Jones, B. J., Ducore, J., Cuker, A., Sullivan, L. M., Majumdar, S., Teitel, J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708538 · Cited by 762
Antioxidants reduce endoplasmic reticulum stress and improve protein secretion
Malhotra, J. D., Miao, H. Z., Zhang, K., Wolfson, A., Pennathur, S., Pipe, S. W., & Kaufman, R. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809677105 · Cited by 682
Flagged first, then by citations
Research works printed but not linked: 1
- Falese L, Gene Ther
Cited by
Sorted by citations
Items 401–500 of 692
Valerieva, A., Caccia, S., & Cicardi, M. (2018) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2018.1503055 · Cited by 10
Pipe, S. W., Kruse‐Jarres, R., Mahlangu, J. N., Pierce, G. F., Peyvandi, F., Kuebler, P., Ford, C. D., Sanabria, F., Ko, R. H., Chang, T. Y., et al. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15186 · Cited by 10
Self-citationFonck, C., Su, C., Arens, J., Koziol, E., Srimani, J. K., Henshaw, J., Tuyl, A. V., Chandra, S. A. M., Vettermann, C., & O’neill, C. A. (2022) · Gene Therapy · doi:10.1038/s41434-022-00318-5 · Cited by 9
Self-citationCastaman, G., Carulli, C., CRISTOFARO, R. D., Follino, M., Lupi, A., Mancuso, M. E., Mansueto, M. F., Molinari, A. C., Pasquetti, P., Santoro, C., et al. (2022) · Haemophilia · doi:10.1111/hae.14709 · Cited by 9
Lisjak, M., Iaconcig, A., Guarnaccia, C., Vicidomini, A., Moretti, L., Collaud, F., Ronzitti, G., Zentilin, L., & Muro, A. F. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.08.022 · Cited by 10
Fletcher, S. J., Jenner, K., Holland, M., & Khair, K. (2024) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-024-03068-2 · Cited by 9
Recino, A., Gan, S. U., Sia, K. C., Sawyer, Y., Trendell, J., Kay, R. G., Gribble, F. M., Reimann, F. M., Foale, R., Notaridou, M., et al. (2018) · Gene Therapy · doi:10.1038/s41434-018-0052-5 · Cited by 9
A non-viral genome editing platform for site-specific insertion of large transgenes
Chaudhari, N., Rickard, A. M., Roy, S., Dröge, P., & Makhija, H. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01890-6 · Cited by 10
Sharma, A., Mathew, M. E., Sriganesh, V., & Reiss, U. M. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010822.pub4 · Cited by 10
Treatment of Hemophilia — More Amazing Progress
Mannucci, P. M. (2020) · New England Journal of Medicine · doi:10.1056/nejme2024545 · Cited by 9
Efficient removal of antibodies to adeno‐associated viruses by immunoadsorption
Boedecker-Lips, S. C., Judel, A., Holtz, S., Mayer, M., Klimpke, P., Kraus, D., Schreiner, T., Gerstmayer, B., Eulitz, K., Mayer, M., et al. (2023) · Journal of Clinical Apheresis · doi:10.1002/jca.22069 · Cited by 8
Why is the uptake of gene therapy in hemophilia less than expected?
Pierce, G. F., Skinner, M. W., O’Mahony, B., Rotellini, D., & Kaczmarek, R. (2025) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2025.102948 · Cited by 8
Self-citationNon-clinical safety considerations on genome editing using the CRISPR/Cas system
Toofan, P., Singh, M., Brööks, A. G., & McLuckie, K. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101785 · Cited by 6
Ultra-sensitive AAV capsid detection by immunocapture-based qPCR following factor VIII gene transfer
Sandza, K., Clark, A., Koziol, E., Akeefe, H., Yang, F., Holcomb, J., Patton, K., Hammon, K., Mitchell, N., Wong, W. Y., et al. (2021) · Gene Therapy · doi:10.1038/s41434-021-00287-1 · Cited by 8
Self-citationCharacteristics of BAY 2599023 in the Current Treatment Landscape of Hemophilia A Gene Therapy
Pipe, S. W., Arruda, V. R., Lange, C., Kitchen, S., Eichler, H., & Wadsworth, S. C. (2022) · Current Gene Therapy · doi:10.2174/1566523222666220914105729 · Cited by 9
Application of Gene Therapy in Hemophilia
Hu, Y., Fang, Y., Lai, Y., Feng, X., & Xu, S. (2022) · Current Medical Science · doi:10.1007/s11596-022-2645-x · Cited by 8
Ex vivo factor VIII ‐modified proliferating human hepatocytes therapy for haemophilia A
Zhang, K., Wu, N., Cen, J., Li, J., Wang, Z., Xia, Q., & Hui, L. (2023) · Cell Proliferation · doi:10.1111/cpr.13467 · Cited by 9
Non-viral and viral delivery systems for hemophilia A therapy: recent development and prospects
Zangi, A. R., Amiri, A., Pazooki, P., Soltanmohammadi, F., Hamishehkar, H., & Javadzadeh, Y. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05459-0 · Cited by 8
Use of CD19-targeted immune modulation to eradicate AAV-neutralizing antibodies
Doshi, B. S., Markmann, C., Novak, N. C., Rojas, S. J., Davidson, R. J., Chau, J. Q., Wang, W., Carrig, S., Rus, C. M., Samelson‐Jones, B. J., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.003 · Cited by 8
Brophy, D. F., Martin, E. J., Ninivaggi, M., Mohammed, B. M., Barrett, J. C., Kuhn, J. G., Nolte, M. E., Waters, E. K., & Ezban, M. (2018) · Haemophilia · doi:10.1111/hae.13597 · Cited by 8
Gene Therapy for Hemophilia A: Where We Stand
Zhou, M., Hu, Z., Zhang, C., Wu, L., Li, Z., & Liang, D. (2020) · Current Gene Therapy · doi:10.2174/1566523220666200806110849 · Cited by 8
Li, J., Chen, J., Schroeder, J. A., Hu, J., Williams, C. B., & Shi, Q. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.12.026 · Cited by 8
Kasprzyk, T., Donnou, S., Long, B. R., Zoog, S. J., & Vettermann, C. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.01.004 · Cited by 8
Self-citationDeng, M., Zhou, H., He, S., Qiu, H., Wang, Y., Zhao, A. Y., Mu, Y., Li, F., & Zhao, A. Z. (2023) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-023-02894-0 · Cited by 8
Re-personalization and stratification of hemophilia care in an evolving treatment landscape
Hart, D. P., Kessler, C. M., & Aledort, L. M. (2019) · Hematology · doi:10.1080/16078454.2019.1687798 · Cited by 8
Gene therapy 1·0 in haemophilia: effective and safe, but with many uncertainties
Makris, M. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30035-1 · Cited by 8
Komatsu, Y., Tanaka, C., Komorizono, R., & Tomonaga, K. (2020) · Scientific Reports · doi:10.1038/s41598-020-62630-7 · Cited by 8
Recent Advances in Gene Therapy for Hemophilia
Pang, X., Fu, J., Zhou, Z., Tang, N., Lau, C., Wen, Y., Chen, P., Zhao, J., & Xue, H. (2025) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296251378455 · Cited by 9
Leavitt, A. D., Mahlangu, J. N., Raheja, P., Symington, E. M., Quon, D. V. K., Giermasz, A., Kenet, G., Lowe, G., Key, N. S., Millar, C. M., et al. (2026) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2026.103416 · Cited by 8
Self-citationImmunogenicity of Therapeutic Biological Modalities - Lessons from Hemophilia A Therapies
Nguyen, N. H., Jarvi, N. L., & Balu‐Iyer, S. V. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.05.014 · Cited by 7
Rodriguez, M., Trevisan, B., Ramamurthy, R. M., George, S. K., Diaz, J., Alexander, J., Meares, D., Schwahn, D. J., Quilici, D. R., Figueroa, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39986-1 · Cited by 7
Bortolussi, G., Iaconcig, A., Canarutto, G., Porro, F., Ferrucci, F., Galletta, C., Díaz-Muñoz, C., Rawat, V., Caneva, A. D., Olajide, O. J., et al. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.101161 · Cited by 7
Jiang, F., Zhang, C., Liu, W., Liu, F., Huang, H., Tan, Y. F., & Qin, B. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1301915 · Cited by 9
Agarwal, S., Sandza, K., Obrochta, K. M., Vora, M., Bowen, A., Bunch, B., Holcomb, J., Robinson, T. M., Jayaram, K., Russell, C. B., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013150 · Cited by 7
Self-citationNavigating Speed Bumps on the Innovation Highway in Hemophilia Therapeutics
DiMichele, D. (2018) · HemaSphere · doi:10.1097/hs9.0000000000000144 · Cited by 7
Crispin, P. J., & Koo, R. M. (2019) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0038-1677020 · Cited by 7
Advances in gene therapy for hemophilia
Robles‐Rodríguez, O. A., Perez‐Trujillo, J. J., Villanueva-Olivo, A., Martinez, L. V., Marfil‐Rivera, L. J., Rodríguez‐Rocha, H., García‐García, A., Cárdenas, O. S., Loera‐Arias, M. D. J., & Montes‐de‐Oca‐Luna, R. (2020) · Journal of Biosciences · doi:10.1007/s12038-020-00057-y · Cited by 7
Heterogeneity in Bleeding Tendency and Arthropathy Development in Individuals with Hemophilia
Rehill, A. M., McCluskey, S., O’Donnell, J. S., Dockal, M., Preston, R. J. S., & on behalf of the iPATH Study Group (2021) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0041-1723769 · Cited by 7
Genome editing in the human liver: Progress and translational considerations
Ginn, S. L., Christina, S., & Alexander, I. E. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.01.030 · Cited by 7
Zhang, L., Yates, B., Murphy, R., Liu, S., Xie, L. Y., Handyside, B., Sihn, C., Bouwman, T., Galicia, N., Tan, D., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.08.002 · Cited by 7
Self-citationOne Health: Animal Models of Heritable Human Bleeding Diseases
Dodds, W. J. (2022) · Animals · doi:10.3390/ani13010087 · Cited by 7
Utilizing adeno‐associated virus as a vector in treating genetic disorders or human cancers
Shih, F., Chang, H.-H., & Wang, Y. (2024) · IUBMB Life · doi:10.1002/iub.2896 · Cited by 7
Gene-based FVIIa prophylaxis modulates the spontaneous bleeding phenotype of hemophilia A rats
Zintner, S. M., Small, J. C., Pavani, G., Dankner, L. E., Marcos-Contreras, O. A., Gimotty, P. A., Kjelgaard-Hansen, M. J., Wiinberg, B., & Margaritis, P. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018027219 · Cited by 7
Gene therapy. The legacy of Wacław Szybalski
Dulak, J. (2021) · Acta Biochimica Polonica · doi:10.18388/abp.2020_5805 · Cited by 7
Gene Therapy for Hemophilia: Are Expectations Matching Reality?
Pierce, G. F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.019 · Cited by 7
Self-citationKwon, H.-J., Qing, K., Ponnazhagan, S., Wang, X.-S., Markusic, D. M., Gupte, S., Boye, S. E., & Srivastava, A. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.018 · Cited by 6
Touramanidou, L., Gurung, S., Cozmescu, A. C., Perocheau, D. P. B., MOULDING, D. A., Deborah, R., Cavedon, A., Siddiqui, S., Rice, L., Finn, P. F., et al. (2024) · Cells · doi:10.3390/cells13231979 · Cited by 6
Adeno-associated virus gene therapy for hemophilia: an update meta-analysis and systematic review
Yang, W., Wang, A., & Liu, B. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1580264 · Cited by 6
Amante, J. J., Twombly, B., Thotathil, N., & Kearney, C. J. (2025) · Biomaterials Science · doi:10.1039/d5bm00623f · Cited by 6
Advances in Gene Therapy Clinical Trials for Hemophilia Care
Rana, A. J., Hussain, M. S., Jakhmola, V., & Gupta, G. (2025) · Current Gene Therapy · doi:10.2174/0115665232413510250904105956 · Cited by 6
Kumar, V., Kalishwaralal, K., Chauhan, C., Singh, G., Barnwal, R. P., & Sharma, S. K. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1678325 · Cited by 6
Dargaud, Y. G., Yamaguti-Hayakawa, G. G., Frade-Guanaes, J. O., Leuci, A., & Ozelo, M. C. (2025) · Blood Reviews · doi:10.1016/j.blre.2025.101353 · Cited by 7
Handyside, B., Zhang, L., Yates, B., Xie, L. Y., Ismail, A. M., Murphy, R., Baridon, B., Su, C., Bouwman, T., Mangini, L., et al. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.065 · Cited by 6
Gene Therapy for Hemophilia B: Achievements, Open Issues, and Perspectives
Castaman, G., & Miesbach, W. (2024) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0044-1787190 · Cited by 6
Transforming Hemophilia A Care: Insights into New Therapeutic Options
Iurea, I.-M., Severin, E. M., & Matei, A. (2024) · Life · doi:10.3390/life14121568 · Cited by 6
Psychotropic Taxonomies: Constructing a Therapeutic Framework for Psychiatry
McCutcheon, R. A., Cowen, P. J., Nour, M. M., & Pillinger, T. (2024) · Biological Psychiatry · doi:10.1016/j.biopsych.2024.12.004 · Cited by 6
Mnyandu, N., Limani, S. W., Ely, A., Wadee, R., Arbuthnot, P. B., & Maepa, M. B. (2025) · Virology Journal · doi:10.1186/s12985-025-02662-5 · Cited by 7
Chen, J.-H., Zhan, L.-J., Lv, C.-M., Teng, J.-B., & Cao, C. (2025) · Current Medical Science · doi:10.1007/s11596-025-00084-6 · Cited by 7
Rasolonjatovo, B., Illy, N., Bennevault, V., Mathé, J., Midoux, P., Gall, T. L., Haudebourg, T., Montier, T., Lehn, P., Pitard, B., et al. (2020) · Macromolecular Bioscience · doi:10.1002/mabi.201900276 · Cited by 6
Canfield, S. L. (2021) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxab064 · Cited by 6
Kovács, O. T., Soltész‐Katona, E., Marton, N., Baricza, E., Hunyady, L., Turu, G., & Nagy, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084221 · Cited by 6
Seroprevalence to adeno‐associated virus type 6 in people with hemophilia B from a UK adult cohort
Boyce, S., James, I., Rangarajan, S., Curry, N. S., Bagot, C. N., Austin, S. K., Laffan, M., Mangles, S., Chandrakumaran, K., & Mundy, C. (2022) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12705 · Cited by 6
Self-citationZou, P. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15597 · Cited by 6
Hemophilia Healing with AAV: Navigating the Frontier of Gene Therapy
Khan, S. U., Khan, M. U., Suleman, M., Inam, A., & Din, M. A. U. (2024) · Current Gene Therapy · doi:10.2174/0115665232279893231228065540 · Cited by 6
Zhang, W., Mao, J., Shen, Y., Zhang, G., Shao, Y., Ruan, Z., Wang, Y., Wu, W., Wang, X., Zhu, J., et al. (2018) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2018.09.004 · Cited by 6
Sfougataki, I., Grafakos, I., Varela, I., Mitrakos, A. K., Karagiannidou, A., Tzanoudaki, M., Poulou, M., Mertzanian, A., Roubelakis, M. G., Stefanaki, K., et al. (2019) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2019.01.003 · Cited by 6
Stem, C. T., Rodman, C., Ramamurthy, R. M., George, S. K., Meares, D., Farland, A. M., Atala, A., Doering, C. B., Spencer, H. T., Porada, C. D., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.678117 · Cited by 6
Defenestrated endothelium delays liver-directed gene transfer in hemophilia A mice
Kaminski, T. W., Ju, E.-M., Gudapati, S., Vats, R., Arshad, S., Dubey, R. K., Katoch, O., Tütüncüoğlu, E., Frank, J., Brzóska, T., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006388 · Cited by 6
Kaczmarek, R. (2018) · Haemophilia · doi:10.1111/hae.13525 · Cited by 6
Gene Therapy in Pediatric Liver Disease
Muro, A. F., D’Antiga, L., & Mingozzi, F. (2019) · Springer eBooks · doi:10.1007/978-3-319-96400-3_44 · Cited by 6
When innovation goes fast. The case of hemophilia
Pilunni, D., Montrasio, L., & Navarra, P. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.06.005 · Cited by 6
Enhancing therapeutic efficacy of in vivo platelet-targeted gene therapy in hemophilia A mice.
Wang, X., Fu, R. Y., Li, C., Chen, C., Firrman, J., Konkle, B. A., Zhang, J., Li, L., Xiao, W., Poncz, M., et al. (2020) · PubMed Central · doi:10.1182/bloodadvances.2020002479 · Cited by 6
Hemophilia gene therapy is effective and safe
Makris, M. (2018) · Blood · doi:10.1182/blood-2018-01-824144 · Cited by 6
Exploiting Viruses to Treat Diseases
Longo, D. L., & Baden, L. R. (2018) · New England Journal of Medicine · doi:10.1056/nejme1807181 · Cited by 6
Liu, W., Pei, X., Yu, T., Xu, B., Dai, X., Xue, F., Chen, L., Wang, X., Wang, Y., Chen, Y., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02599-3 · Cited by 6
Transforming Hemophilia Management: Lessons from Gene Therapy Clinical Trials
Hussain, M. S., Maqbool, M., Arab, M. M., Rana, A. J., Ashique, S., Khan, Y., Jakhmola, V., & Gupta, G. (2025) · Molecular Biotechnology · doi:10.1007/s12033-025-01464-y · Cited by 5
Santos, S., Robinson, T. M., & Trueman, D. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03368-4 · Cited by 5
Bergmeier, W., Antoniak, S., Conway, E. M., Denis, C. V., George, L. A., Isermann, B., Key, N. S., Krishnaswamy, S., Lam, W. A., Lillicrap, D., et al. (2018) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12095 · Cited by 5
Proof-of-concept study for liver-directed miQURE technology in a dyslipidemic mouse model
Zancanella, V., Vallès, A., Liefhebber, J. M. P., Paerels, L., Vendrell‐Tornero, C., Wattimury, H., van der Zon, T., van Rooijen, K., Golinska, M. A., Grevelink, T., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.04.004 · Cited by 5
Brimble, M. A., Morton, C. L., Winston, S. M., Reeves, I. L., Spence, Y., Cheng, P.-H., Zhou, J., Nathwani, A. C., Thomas, P. G., Souquette, A. H., et al. (2024) · Human Gene Therapy · doi:10.1089/hum.2023.188 · Cited by 5
Precision and efficacy of RNA-guided DNA integration in high-expressing muscle loci
Padmaswari, M. H., Bulliard, G. N., Agrawal, S., Jia, M. S., Khadgi, S., Murach, K. A., & Nelson, C. E. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102320 · Cited by 5
New technologies in gene therapy for inducing immune tolerance in hemophilia A
Borsotti, C., & Follenzi, A. (2018) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2018.1539667 · Cited by 5
A rAAV2/6 Mutant with Enhanced Targeting for Mouse Retinal Müller Cells
Cao, J., Liu, X., Yuan, Y., Wang, F., Kong, W., Shi, G., Li, W., & Zhang, C. (2019) · Current Eye Research · doi:10.1080/02713683.2019.1639768 · Cited by 5
Elnaggar, M., Al-Mohannadi, A., Kizhakayil, D., Raynaud, C. M., Al-Mannai, S., Gentilcore, G., Pavlovski, I., Sathappan, A., van Panhuys, N., Borsotti, C., et al. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.11.003 · Cited by 5
Targeting Age-Related Neurodegenerative Diseases by AAV-Mediated Gene Therapy
Cagin, U. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-55035-6_15 · Cited by 5
Optimizing bleed prevention throughout the lifespan: Womb to Tomb
Gupta, S. K., & Shapiro, A. D. (2018) · Haemophilia · doi:10.1111/hae.13471 · Cited by 5
Hay, C. E., Gonzalez, G. A., Ewing, L., Reichard, E. E., Hambuchen, M. D., Nanaware‐Kharade, N., Alam, S., Bolden, C., Owens, S. M., Margaritis, P., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0200060 · Cited by 5
Wang, D., Shao, X., Wang, Q., Pan, X., Dai, Y., Yao, S., Tong, Y., Wang, Z., Zhu, J., Xi, X., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.375 · Cited by 5
Napolitano, M., & Kessler, C. M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-46202-0.00003-0 · Cited by 5
Gene therapy for hemophilias: the end of phenotypic testing or the start of a new era?
Lippi, G., & Favaloro, E. J. (2020) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000905 · Cited by 5
Gene therapy trials for haemophilia: a step closer to a cure?
Batty, P. A., & Pasi, J. (2019) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2019.1632704 · Cited by 5
Hybrid LC–MS as A Powerful Tool for Supporting Protein Bioanalysis in Gene and Cell Therapies
Dong, W., Kim, Y., Sugimoto, H., Dong, L., & Qian, M. G. (2020) · Bioanalysis · doi:10.4155/bio-2020-0147 · Cited by 5
An AAV-Based NF-κB-Targeting Gene Therapy (rAAV-DMP-miR533) to Inflammatory Diseases
Luo, T., Wang, Y., Tang, H., Zhou, F., Chen, Y., Pei, B., & Wang, J. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s362732 · Cited by 4
Gong, J., Yang, R., Zhou, M. Q., & Chang, L. (2023) · Molecular Medicine · doi:10.1186/s10020-023-00680-z · Cited by 4
The evolving landscape of gene therapy for congenital severe hemophilia: a 2024 state of the art
Minno, G. D., Spadarella, G., Calcaterra, I. L., Castaman, G., Simioni, P., CRISTOFARO, R. D., Santoro, C., Peyvandi, F., & Minno, M. N. D. D. (2024) · Bleeding Thrombosis and Vascular Biology · doi:10.4081/btvb.2024.144 · Cited by 4
Research Status and Applications of Adeno‐Associated Virus
Xia, K., Liu, S., Wu, Z., & Jiang, J. (2024) · ChemBioChem · doi:10.1002/cbic.202400856 · Cited by 4
Progress in Gene Therapy for Hereditary Tyrosinemia Type 1
Thomas, H., & Carlisle, R. C. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17030387 · Cited by 4
mGem: AAV, from almost a virus to an awesome vector—or is it?
Srivastava, A. (2026) · mBio · doi:10.1128/mbio.02957-25 · Cited by 5
Precise and efficient DNA base editing restores normal hearing in adult DFNB9 mouse model
Zhang, Z., Wang, M., Tan, F., Zhang, L., Wang, X., Chen, X., Han, J., Li, N., Sun, Q., Lu, Y., et al. (2026) · Med · doi:10.1016/j.medj.2026.101001 · Cited by 4
T2 Magnetic Resonance to Monitor Hemostasis
Cuker, A. C., Marturano, J. E., Carinato, M. E., Lowery, T. J., & Cines, D. B. (2018) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0038-1667114 · Cited by 4
Metadata
- Authors
- Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G. F., Wong, W. Y., & Pasi, K. J.
- Affiliations
- University Hospitals Birmingham NHS Foundation Trust (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-12-28
- Volume
- 377
- Issue
- 26
- Pages
- 2519-2530
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2775538622
- Cited by
- 694
- References
- 29
- Citations by year
- 2026: 33 · 2025: 59 · 2024: 65 · 2023: 57 · 2022: 95 · 2021: 81 · 2020: 112 · 2019: 90 · 2018: 95 · 2017: 5
- FWCI
- 63.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- BioMarin Pharmaceutical
- University Hospitals Birmingham NHS Foundation Trust
- National Institute for Health and Care Research
- University of Cambridge
- Imperial College London
- Imperial College Healthcare NHS Trust
- Barts Health NHS Trust
- Topics
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Keywords
- hemophilia A, gene therapy, factor VIII, B-domain-deleted factor VIII, codon optimization, annualized bleeding rate, factor VIII activity, dose escalation, alanine aminotransferase elevation, chronic arthropathy, neutralizing antibodies
- MeSH terms
- Dependovirus, Adult, Antibodies, Viral, DNA, Viral, Factor VIII, Genetic Vectors, Hemophilia A, Hemorrhage, Humans, Infusions, Intravenous, Male, Genetic Therapy, Virus Shedding, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
